key: cord-0307782-jo2f48aw
authors: Jonsdottir, Hulda R.; Siegrist, Denise; Julien, Thomas; Padey, Blandine; Bouveret, Mendy; Terrier, Olivier; Pizzorno, Andres; Huang, Song; Samby, Kirandeep; Wells, Timothy N.C.; Boda, Bernadett; Rosa-Calatrava, Manuel; Engler, Olivier B.; Constant, Samuel
title: Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro
date: 2022-01-10
journal: bioRxiv
DOI: 10.1101/2022.01.10.475377
sha: 94ede4ed15c69689e49abf4eea16cb9d14073ce2
doc_id: 307782
cord_uid: jo2f48aw

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in late 2019, has caused a worldwide pandemic with unprecedented economic and societal impact. Currently, several vaccines are available, and multitudes of antiviral treatments have been proposed and tested. Although many of the vaccines show high clinical efficacy, they are not equally accessible worldwide. Additionally, due to the continuous emergence of new virus variants, and generally short duration of immunity, the development of safe and effective antiviral treatments remains of the utmost importance. Since the emergence of SARS-CoV-2, substantial efforts have been undertaken to repurpose existing and approved drugs for accelerated clinical testing and potential emergency use authorizations. However, drug-repurposing using high throughput screenings in cellular assays, often identify hits that later prove ineffective in clinical studies. Our approach was to evaluate the activity of compounds that have either been tested clinically or already undergone extensive preclinical profiling, using a standardized in vitro model of human nasal epithelium. Secondly, we evaluated drug combinations using sub-maximal doses of each active single compound. Here, we report the antiviral effects of 95 single compounds and 30 combinations. The data show that selected drug combinations including 10 μM of molnupiravir, a viral RNA-dependent RNA polymerase (RdRp) inhibitor, effectively inhibit SARS-CoV-2 replication. This indicates that such combinations are worthy of further evaluation as potential treatment strategies against coronavirus disease 2019 (COVID-19).

In December 2019, a novel coronavirus (CoV) causing respiratory illness in humans was identified in Wuhan, China (1) . In the following months, this virus, designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2), spread to every continent and currently there have been over 290 million documented cases worldwide and over 5 million deaths (3) .

The corresponding illness, termed coronavirus disease 2019 (COVID- 19) , presents with a range of symptoms and severity (4) (5) (6) (7) (8) . The acute respiratory disease syndrome (ARDS) observed in severe cases of COVID-19 is driven by the cytokine storm, characterized by uncontrolled overproduction of soluble immune mediators. This results in sustained inflammation and tissue injury that can lead to low oxygenation and eventual death (9, 10) . A recurring pattern of upregulation of pro-inflammatory cytokines, including IL-6, IL-1β, and TNF-α has been observed (11, 12) with additional secretion of various chemokines (MCP-1, IP-10, RANTES) resulting in the influx of immune cells into the pulmonary space (13) (14) (15) (16) .

Despite the rapid development and current availability of several vaccines, effective and safe treatments against COVID-19 are still of extreme importance due to incomplete vaccine uptake, incomplete protective response, and the relatively short duration of immunity.

Additionally, those who either cannot be vaccinated or choose not to be, are not protected against severe COVID-19. Development of new treatments traditionally takes many years; however, the rapid spread of the virus means that new treatment options against SARS-CoV-2 are urgently needed. Drug repurposing redirects existing or previously approved drugs as new therapeutics for new clinical indications in a time-and cost-effective manner. For example, remdesivir (also known as GS-5734) an intravenous ProTide prodrug (17) targeting the RNAdependent RNA polymerase (RdRp) of Hepatitis C virus, was repurposed and conditionally approved as emergency treatment for COVID-19 early in the pandemic (18) . However, due to the complex interplay between the host immune system and virus replication, drugs inhibiting viral replication alone are often not sufficient to fight the systemic viral infection and resulting sequelae. For early ambulatory treatment of COVID-19, various treatments combining compounds targeting viral replication with other drugs have been proposed to maximize therapeutic potential (19) (20) (21) . In addition, experiences gained through the development of therapeutic strategies against other RNA viruses (e.g., HIV, HCV) underline the importance of combining several drugs targeting different viral proteins and/or host factors to prevent the emergence of drug resistant mutants (22) (23) (24) . Due to the heterogeneity of in vitro cell lines used in different studies, direct comparison of drug efficacy is difficult. To allow better comparison of compounds, we developed a standardized in vitro screening model, using fully differentiated primary human nasal epithelium (MucilAir™). Applying a standardized test protocol, we reevaluated a collection of compounds from the Medicines for Malaria Venture (MVV) open access collections (25) and the Calibr ReFRAME drug-repurposing library (26) . In the current study, we assessed the antiviral potential of 99 single compounds at two study sites with a focus on orally active drugs. Subsequently, we selected molnupiravir, an orally bioactive RdRp inhibitor recently approved by the American Food and Drug Administration (FDA), as a base compound for combination therapy (27) . We evaluated various concentrations of 30 drugs in combination with 10 µM molnupiravir and found that selected combinations have the potential to boost antiviral activity compared to single treatments, indicating a benefit of combined antiviral treatment against SARS-CoV-2.

Human nasal epithelial cells were obtained from patients undergoing polypectomy, experimental procedures were explained in full, and all subjects provided informed consent.

The study was conducted according to the declaration of Helsinki (Hong Kong amendment, 1989), and received approval from local ethics commissions. Cells were isolated from primary tissue as previously described (28) and expanded once (p1). Pooled nasal epithelial cells from 14 individual donors were then seeded on 6.5-mm Transwell ® inserts (cat #3470, Corning Incorporated, Oxyphen, Wetzikon, Switzerland) in MucilAir™ culture medium (EP04MM, Epithelix Sàrl, Geneva, Switzerland). Once confluent, air-liquid interface (ALI) was established and maintained for at least 28 days for mucociliary differentiation. Average culture time post ALI was 43 days.

Compounds were sourced from Calibr (California Institute for Biomedical Research, La Jolla, California, USA) or from MMV except for IFN-α (IF007 #3308269), IFN-λ (SRP3060), ebselen (E3520), dalbavancin (SML-2378) and nanchangmycin (SML2251 #0000040357) which were purchased from Sigma Aldrich (Buchs SG, Switzerland), while IFN-β (AF-300-02B) was sourced from Peprotech (LubioScience GmbH, Zürich, Switzerland). Compounds were selected using available data from primary screens using various cell lines (Vero E6, HeLa-ACE2, Calu-3) and organoids and were obtained blinded as 10 mM stock solution in dimethyl sulfoxide (DMSO). Compound toxicity (n=104) was evaluated by assessing the release of lactate dehydrogenase (LDH, Assay Kit-WST CK12-20, Dojindo EU, Munich, Germany) from damaged cells at 48 and 72h post treatment. Compound-containing cell culture media was replenished every 24h. Trans-epithelial electrical resistance (TEER) was monitored at 24, 48, and 72h, while ciliary beating frequency (CBF) was assessed at 72h by capturing 256 images at a high frequency rate (125 frames per second) at room temperature (RT). CBF was calculated using Cilia-X software (Epithelix Sàrl, Geneva, Switzerland). 

Prior to infection, MucilAir™ reconstituted nasal epithelium, was washed twice with OptiMEM (Gibco) warmed to 37°C and basal media replenished with warm MucilAir™ cell culture media. 5x10 4 TCID50 of SARS-CoV-2 (for a theoretical MOI of 0.1) were added to the apical compartment diluted in OptiMEM and incubated at 37°C, 5% CO2 and >85% rH for 1h.

Mock controls were exposed to the same volume of OptiMEM only. Subsequently, virus inoculum was removed, and the epithelium transferred to cell culture media containing test or control compounds. Apical virus release was assessed at 48 and 72 hpi by washing the apical side with 200 µl OptiMEM for 10 min at 37°C. During harvest of viral particles from the apical compartment, while the epithelium is submerged, TEER was assessed as described above. Test and control compounds were replenished every 24 h for the duration of the experiment (72h).

Remdesivir was applied as a positive control at a concentration of 5 M (Gilead Sciences Inc., Foster City, California, USA or MedChemExpress, (HY-104077)). All compounds were diluted in DMSO and final concentration of DMSO in the antiviral assay was standardized as 0.3% for single compounds and 0.4% for combinations. Experimental layout is presented in and reported as tissue culture infectious dose 50 per ml (TCID50/ml). 

Statistical significance between single molnupiravir treatments and combinations were determined by ordinary one-way analysis of variance (ANOVA) with Dunnett's multiple comparison test. Significance between single and combination treatment for other compounds was determined by ordinary one-way ANOVA with Sidak's multiple comparison test. p-values <0.05 were considered statistically significant.

Tolerated Table S1 . Examples of a well-tolerated compound, molnupiravir, and a compound inducing toxic effects, LY2228820, are shown in Figure S1 . A decrease in TEER is a clear indicator of cellular toxicity in this system and its measurement is compatible with virus replication and high biosafety laboratory constraints.

Interestingly, when measuring TEER in infection/treatment experiments, some of the tested substances including osimertinib, midostaurine, ZLVG CHN2 and ozanimod, led to a loss of epithelial integrity (TEER<100 Ω.cm 2 ) beyond that observed for vehicle control. Such compounds were excluded from further analysis.

We intracellularly at the highest concentration tested (Figure 2) .

Molnupiravir, which has since demonstrated clinical efficacy, was chosen as the basis compound to evaluate drug combinations as a treatment option against SARS-CoV-2 infection.

Using pooled data from two testing sites, a dose response curve (Figure 3 ) of the fold change in genome copies following treatment with molnupiravir estimated IC50 at 11.1 µM (Figure 3 ). Similar IC50 of 9.2 µM was calculated for molnupiravir using infectious titer in apical wash ( Figure 3c ). Based on these data, the concentration of molnupiravir was set to 10 µM in combination treatments.

Overall, 30 combinations were tested at various concentrations (48 different conditions, Table   S2 ). Treatment of SARS-CoV-2 infected re-constituted epithelium with 10 µM molnupiravir alone resulted in a moderate 2 log reduction in viral RNA both in apical wash and intracellularly (Figure 3a 

The secretion of two major chemokines induced by SARS-CoV-2 infection, IP-10/CXCL-10 and RANTES/CXCL-5, was moderate, with an average of 4.5 and 9.2-fold increase over mock respectively. In the combination treatments, we did not observe any robust pattern of inhibition.

IP-10 secretion was generally low, and only significantly reduced in combination treatment with remdesivir (p<0.0001). For nafamostat, ivermectin, ONO-3307, and brequinar no reduction was observed after the addition of molnupiravir ( Figure S3a ) while a slight nonsignificant reduction was observed for alisporivir and TO-195. A similar pattern was observed for RANTES ( Figure S3b ).

Despite current access to vaccination against SARS-CoV-2, safe and effective antiviral treatment options should be pursued and refined for human use. For optimal antiviral treatment, Additionally, when combined with Favipiravir, antiviral activity of molnupiravir against SARS-CoV-2 in Syrian hamsters was enhanced (44) , further highlighting the potential benefits of combination therapies. Molnupiravir is also orally bioactive, making its administration easy and straightforward. Furthermore, combination treatments could require lower dosages of single active compounds potentially providing additional therapeutic benefits.

In conclusion, the herein reported molnupiravir-based combination treatments increased antiviral activity against SARS-CoV-2 compared to single treatments in reconstituted nasal epithelium. Further studies focusing on the precise additive or synergistic effect of molnupiravir-based combinations are needed to provide a more comprehensive idea of their treatment potential.

Conceptualization 

A Novel Coronavirus from Patients with Pneumonia in China

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

COVID-19) Dashboard

Characteristics of asymptomatic COVID-19 infection and progression: A multicenter, retrospective study

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system

Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration

An inflammatory cytokine signature predicts COVID-19 severity and survival

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Chemokines and chemokine receptors during COVID-19 infection. Computational and structural biotechnology journal

Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease

The ProTide Prodrug Technology: From the Concept to the Clinic

Remdesivir for the Treatment of Covid-19 -Final Report

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)

Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents

Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection

The global burden of HIV-1 drug resistance in the past 20 years

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens

Rapid emergence of protease inhibitor resistance in hepatitis C virus

The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis

Molnupiravir, an Oral Antiviral Treatment for COVID-19

Long-term cultures of polarized airway epithelial cells from patients with cystic fibrosis

Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia

Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie

THE METHOD OF 'RIGHT AND WRONG CASES' ('CONSTANT STIMULI') WITHOUT GAUSS'S FORMULAE

A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12

Determination of 50% endpoint titer using a simple formula

GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Current status and prospects of HIV treatment

Hepatitis C virus: standard-of-care treatment

Drug combination therapy for emerging viral diseases

Antiviral drug screening by assessing epithelial functions and innate immune responses in human 3D airway epithelium model

Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebocontrolled, randomized clinical trial

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

White column: Mock (uninfected control), dark grey column: infected vehicle control containing 0.3 % DMSO (VC), black column: 10 µM molnupiravir alone

Statistical significance between single agents and combinations are represented numerically. Data are represented as mean ± SD

We thank Monalisa Chatterji, Robert Jordan and Betsy Russell from the Bill and Melinda Gates